A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…Oligomeric Alpha-synuclein in Erythrocyte Membrane in Early Parkinson’s Disease
Objective: To determine whether α-synuclein concentrations in the cell membrane and cytoplasm of erythrocytes are altered in PD patients and to evaluate their potential role…GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease
Objective: To assess the 3-month efficacy and safety of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease. Background: A systematic review reported that sialorrhea affects approximately…Atropine as Alternate Therapy for Treatment of Sialorrhea in Parksinson’s Disease
Objective: Evaluating effectiveness of sublingual Atropine 1% ophthalmic solution for treatment of sialorrhea in Parkinson’s disease. Background: Sialorrhea is common non-motor symptom of Parkinson’s disease.…Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data
Objective: To evaluate the opicapone (OPC) associated patient’s odds ratio (OR) in relative OFF-time reduction. Background: OPC, a once-daily COMT inhibitor, proved effective in the…A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results
Objective: The efficacy of isradipine to slow progression of disability in de novo PD participants. Background: There remains no proven therapy to slow progression of…Two-year outcome of autologous peripheral nerve grafting to the substantia nigra at the time of DBS surgery in patients with Parkinson’s disease
Objective: Assess 2-year safety, feasibility, and clinical outcomes of implanting a unilateral peripheral nerve graft to the substantia nigra in patients with Parkinson’s disease at…Cerebellar ataxia and cutaneous lesions: a clinical case
Objective: Highlight the complex differential diagnosis of ataxia in a patient with cutaneous lesions. Background: Cerebellar ataxias may accompany neurocutaneous syndromes. XP is a rare…Phosphodiesterase inhibitors as a treatment for Friedreich’s ataxia
Objective: To evaluate the effect of phosphodiesterase inhibitors, as potential treatment for Friedreich’s ataxia, in a Drosophila melanogaster model of the disease. Background: Friedreich’s ataxia…Clinical and genetic heterogeneity in Indian subcontinent patients with Autosomal Dominant Spinocerebellar Ataxia 42
Objective: We describe the case of a family of 2 female siblings of Indian subcontinent with genetically proven SCA 42 Background: Spinocerebellar ataxia (SCA) are…
- « Previous Page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- …
- 217
- Next Page »